EFAVIRENZ/EMTRICITABINA/TENOFOVIR DISOPROXIL ZENTIVA K.S 600mg / 200mg / 245mg tablets medication leaflet

J05AR06 • efavirenz + emtricitabine + tenofovir disoproxil • Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations

The combination of Efavirenzum + Emtricitabinum + Tenofovirum disoproxil is used for the treatment of HIV-1 infection in adults and adolescents. It combines a non-nucleoside reverse transcriptase inhibitor (efavirenzum) with two nucleoside reverse transcriptase inhibitors (emtricitabinum and tenofovirum disoproxil) to suppress viral replication.

The medication is taken orally, usually once daily, and is effective in reducing viral load and increasing CD4 cell counts. It is used as part of combination antiretroviral therapy.

Side effects may include nausea, dizziness, insomnia, rash, and, in rare cases, liver or kidney impairment. Regular monitoring of liver and kidney function is essential.

Consult your doctor to discuss the benefits and risks of treatment with this combination. Follow the prescribed dosage and adhere to all medical recommendations.